J&J/Caprion
This article was originally published in The Gray Sheet
Executive Summary
In vitro blood test for the human equivalent of mad cow disease, Creutzfeldt-Jacob disease (CJD), will be developed by the Ortho-Clinical Diagnostics unit of Johnson & Johnson under an exclusive, worldwide license agreement with Caprion Pharmaceuticals. The test will be based on prion technologies related to the monoclonal antibodies for CJD. Roche and Prionics also inked an agreement earlier this year for development of a CJD blood test (1"The Gray Sheet" Jan. 29, 2001, In Brief)...
You may also be interested in...
Abbott, ProMetic Pacts With Red Cross Cover Blood Screening, TSE Removal
The American Red Cross will retain a 74% equity stake in a joint venture with ProMetic Life Sciences to develop systems for detection and removal of transmissible spongiform encephalopathy (TSE) pathogens from blood and blood components
Roche Diagnostics/Prionics
Firms will collaborate in development of a blood test for the detection of Creutzfeldt-Jacob disease in humans under an agreement announced Jan. 24. CJD is related to bovine spongiform encephalopathy (BSE), or "mad cow disease." The deal also calls for Roche to distribute the Prionics-Check rapid test for the detection of BSE in dead cattle effective Feb. 1
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.